What is Kymera Therapeutics's change in accrued liabilities?

Kymera Therapeutics (KYMR) reported change in accrued liabilities of -$7.21M in Q1 2026.

How has Kymera Therapeutics's change in accrued liabilities changed year-over-year?

Kymera Therapeutics's change in accrued liabilities increased by 38.3% year-over-year, from -$11.69M to -$7.21M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Kymera Therapeutics KYMR Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

ImmunityBio, Inc.IBRX

$3.14M+124%

Krystal Biotech, Inc.KRYS

-$6.31M-271%

Protagonist TherapeuticsPTGX

-$10.79M+8.7%

Spyre Therapeutics, Inc.SYRE

$3.65M+161%

IncyteINCY

-$84.73M-213%

Apogee Therapeutics, Inc.APGE

$4.67M+77.0%

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's change in accrued liabilities?: Kymera Therapeutics (KYMR) reported change in accrued liabilities of -$7.21M in Q1 2026.
How has Kymera Therapeutics's change in accrued liabilities changed year-over-year?: Kymera Therapeutics's change in accrued liabilities increased by 38.3% year-over-year, from -$11.69M to -$7.21M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.